These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28302409)

  • 1. Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis.
    Lansbury LE; Smith S; Beyer W; Karamehic E; Pasic-Juhas E; Sikira H; Mateus A; Oshitani H; Zhao H; Beck CR; Nguyen-Van-Tam JS
    Vaccine; 2017 Apr; 35(16):1996-2006. PubMed ID: 28302409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses.
    Yin JK; Chow MY; Khandaker G; King C; Richmond P; Heron L; Booy R
    Vaccine; 2012 May; 30(21):3209-22. PubMed ID: 22387221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies.
    Belongia EA; Simpson MD; King JP; Sundaram ME; Kelley NS; Osterholm MT; McLean HQ
    Lancet Infect Dis; 2016 Aug; 16(8):942-51. PubMed ID: 27061888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children.
    Örtqvist Å; Bennet R; Hamrin J; Rinder MR; Lindblad H; Öhd JN; Eriksson M
    Vaccine; 2015 May; 33(22):2558-61. PubMed ID: 25869891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).
    Valenciano M; Kissling E; Reuss A; Jiménez-Jorge S; Horváth JK; Donnell JM; Pitigoi D; Machado A; Pozo F;
    Vaccine; 2015 Jun; 33(24):2813-22. PubMed ID: 25936723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.
    Gefenaite G; Tacken M; Bos J; Stirbu-Wagner I; Korevaar JC; Stolk RP; Wolters B; Bijl M; Postma MJ; Wilschut J; Nichol KL; Hak E
    PLoS One; 2013; 8(6):e66125. PubMed ID: 23840413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.
    Valenciano M; Kissling E; Reuss A; Rizzo C; Gherasim A; Horváth JK; Domegan L; Pitigoi D; Machado A; Paradowska-Stankiewicz IA; Bella A; Larrauri A; Ferenczi A; ; Lazar M; Pechirra P; Korczyńska MR; Pozo F; Moren A;
    Euro Surveill; 2016; 21(7):pii=30139. PubMed ID: 26924024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?
    Mahmud SM; Bozat-Emre S; Hammond G; Elliott L; Van Caeseele P
    PLoS One; 2015; 10(11):e0142754. PubMed ID: 26600435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 - 2018 season.
    Bella A; Gesualdo F; Orsi A; Arcuri C; Chironna M; Loconsole D; Napoli C; Orsi GB; Manini I; Montomoli E; Alfonsi V; Castrucci MR; Rizzo C
    Expert Rev Vaccines; 2019 Jun; 18(6):671-679. PubMed ID: 31159616
    [No Abstract]   [Full Text] [Related]  

  • 10. Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controls.
    Hellenbrand W; Jorgensen P; Schweiger B; Falkenhorst G; Nachtnebel M; Greutélaers B; Traeder C; Wichmann O
    BMC Infect Dis; 2012 May; 12():127. PubMed ID: 22650369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and sensitivity analysis of the effectiveness of unadjuvanted A(H1N1)pdm09 vaccine in hospital workers using multi-center cohort study in Korea.
    Lim J; Choi B; Kim J; Kim J; Kim C; Park J; Yoon H; Hong S; Seo J; Ki M
    Vaccine; 2013 May; 31(19):2381-6. PubMed ID: 23499597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study.
    Steens A; Wijnans EG; Dieleman JP; Sturkenboom MC; van der Sande MA; van der Hoek W
    BMC Infect Dis; 2011 Jul; 11():196. PubMed ID: 21767348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013-2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated.
    Ohmit SE; Petrie JG; Malosh RE; Johnson E; Truscon R; Aaron B; Martens C; Cheng C; Fry AM; Monto AS
    J Infect Dis; 2016 Apr; 213(8):1229-36. PubMed ID: 26597255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza.
    Ortqvist A; Bennet R; Rinder MR; Lindblad H; Eriksson M
    Vaccine; 2012 Aug; 30(39):5699-702. PubMed ID: 22819987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.
    Girard MP; Katz JM; Pervikov Y; Hombach J; Tam JS
    Vaccine; 2011 Oct; 29(44):7579-86. PubMed ID: 21856358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis.
    Domnich A; Arata L; Amicizia D; Puig-Barberà J; Gasparini R; Panatto D
    Vaccine; 2017 Jan; 35(4):513-520. PubMed ID: 28024956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection provided by influenza vaccine against influenza-related hospitalisation in ≥65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19.
    Pebody R; Whitaker H; Zhao H; Andrews N; Ellis J; Donati M; Zambon M
    Vaccine; 2020 Jan; 38(2):173-179. PubMed ID: 31653528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children.
    Van Buynder PG; Dhaliwal JK; Van Buynder JL; Couturier C; Minville-Leblanc M; Garceau R; Tremblay FW
    Influenza Other Respir Viruses; 2010 Jul; 4(4):171-8. PubMed ID: 20629771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
    Chada KE; Forshee R; Golding H; Anderson S; Yang H
    Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.